3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia
33
Leukemia, Myeloid, Acute
31
Leukemia, Lymphocytic, Chronic, B-Cell
28
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Myelodysplastic Syndromes
18
Lymphoma, Non-Hodgkin
18
Lymphoma
17
Hodgkin Disease
16
Multiple Myeloma
12
Lymphoma, Mantle-Cell
11
Recurrence
10
Melanoma
10
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Follicular
10
Lymphoma, B-Cell, Marginal Zone
10
Leukemia, Myelomonocytic, Chronic
10
Burkitt Lymphoma
10
Waldenstrom Macroglobulinemia
8
Neoplasms, Plasma Cell
8
Neoplasm Metastasis
8
Myeloproliferative Disorders
8
Leukemia, Myeloid, Accelerated Phase
8
Lymphoma, Large-Cell, Immunoblastic
7
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Leukemia, Biphenotypic, Acute
7
Hematologic Neoplasms
7
Congenital Abnormalities
7
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, B-Cell
6
Interventions
Ipilimumab
5
Nivolumab
4
pembrolizumab
3
sargramostim
2
fludarabine
2
binimetinib
2
aldesleukin
2
Interleukin-2
2
Granulocyte-Macrophage Colony-Stimulating Factor
2
Cyclophosphamide
2
trametinib
1
tebentafusp
1
sotrastaurin
1
montanide ISA 51
1
incomplete Freund's adjuvant
1
glembatumumab vedotin
1
fludarabine phosphate
1
entrectinib
1
Valproic Acid
1
Tramadol
1
Thalidomide
1
Temozolomide
1
Solutions
1
Ruthenium-106
1
Radiotherapy
1
RNA, Messenger
1
Protein Kinase C
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Ibuprofen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uveal Melanoma
×
fludarabine phosphate
×
Clear all
NCT07627698
2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled